Advertisements

Skiacol 0.5%

Quick links to important sections

Skiacol 0.5%

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Skiacol 0.5%

Quick Facts

Property Description
Active ingredient Cyclopentolate hydrochloride
Form Ophthalmic solution (Eye drop)
Pharmacological class Anticholinergic agent (Muscarinic antagonist)
Common use Diagnostic procedures (Ophthalmic examination)
Origin Synthetic compound

Skiacol 0.5% is a synthetic ophthalmic solution used exclusively for diagnostic purposes to prepare the eye for a thorough medical examination. Its function is based on the action of its active ingredient, Cyclopentolate hydrochloride, which is classified as an anticholinergic agent (muscarinic antagonist). This drug is principally employed for cycloplegic refraction and fundus examination. This reflects the medicine's primary role in enabling precise diagnostic assessments. The drug is clinically recognized for its rapid onset compared to older mydriatic agents, which is a key distinguishing feature for optimizing examination time.


What Type of Ophthalmic Solution is Skiacol 0.5%?

Skiacol 0.5% is categorized as a parasympatholytic medication, meaning it temporarily blocks specific signals within the nervous system that control the eye's involuntary muscles. This drug is a sterile, single-ingredient aqueous solution intended solely for topical ophthalmic administration as an eye drop. This drug is used for its foundational role in standard eye care practice. This demonstrates the targeted, temporary nature of the drug's effect on the eye's muscle function, which is characterized by a short-acting profile.


The Defining Actions: Mydriasis and Cycloplegia (High-Level Effect)

The medication achieves its purpose by inducing two temporary physiological effects: mydriasis (pupil widening) and cycloplegia (temporary paralysis of the eye's focusing muscle). By temporarily suspending the eye’s focusing power through cycloplegia, the professional can take a precise refractive error measurement—the necessary lens power—that is not distorted by the eye’s natural, involuntary focusing effort. This dual effect ensures the integrity of the diagnostic findings, which is a common use scenario in ophthalmology clinics globally.

Regulatory References

  1. MedlinePlus Cyclopentolate Overview
  2. WHO Essential Medicines List
Advertisements

What side effects are possible with Skiacol 0.5%?

Possible Side Effects and Safety Information

The officially documented safety profile for Skiacol 0.5% (Cyclopentolate hydrochloride) is classified by both transient local effects and potential systemic reactions arising from the drug's anticholinergic nature. The adverse reactions are categorized based on frequencies derived from clinical trials and post-marketing surveillance as reported in regulatory documents.

Adverse Reactions by System and Frequency

Classification Organ System Affected Examples of Reported Effects (High-Level)
Common Eye Disorders Transient stinging or burning sensation upon instillation, blurred vision, and photophobia (light sensitivity).
Not Known Cardiac, Nervous System, Psychiatric Disorders Systemic effects may include increased heart rate (tachycardia), dizziness, nausea, confusion, and dry mouth.

Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies that serious adverse reactions, although not frequently reported, primarily involve the central nervous system (CNS) and cardiorespiratory system. These include reports of acute psychotic reactions, convulsions, and rare instances of cardiopulmonary failure, emphasizing the risk associated with systemic absorption.

Population-Specific Considerations: The official safety profile notes a significantly increased risk of CNS toxicity in the pediatric population (children and infants). Additionally, caution is advised for older adults due to the risk of precipitating angle-closure glaucoma from increased intraocular pressure (IOP).

The medicine is strictly contraindicated in individuals with narrow-angle glaucoma or a known hypersensitivity to the drug, as mandated by official regulatory limitations.

Advertisements

Overdose and Emergency Response

Official Overdose Manifestations

Overdose of Skiacol 0.5% (Cyclopentolate hydrochloride) is associated with systemic anticholinergic toxicity, primarily affecting the Central Nervous System (CNS) and cardiovascular system. Documented CNS manifestations include psychotic reactions, disorientation, incoherent speech, restlessness, and hyperactivity. More severe presentations may involve seizures and coma. Systemic effects listed in regulatory documents include hyperpyrexia (fever), flushed or dry skin, urinary retention, and diminished gastrointestinal motility. Cardiovascular findings may present as tachycardia (rapid pulse), irregular pulse, and circulation failures.

Severe Outcomes and Mandatory Emergency Actions

Officially documented severe outcomes of overdose include medullary paralysis, cardiopulmonary failure, and death. Because of the potential for severe systemic toxicity, regulatory information mandates that a patient must seek immediate medical attention for any suspected overdose or for the onset of severe systemic manifestations. If accidental ingestion occurs, official guidance requires immediately contacting a poison control center or presenting to the nearest emergency department for urgent medical care.

Management and Population Risk

For life-threatening toxicity, the official documents specify the use of Physostigmine salicylate as the antidote of choice, alongside general supportive management. Regulatory labeling highlights that infants and young children have an increased susceptibility to severe CNS and cardiopulmonary side effects. Specific risks, such as necrotizing enterocolitis (NEC), are documented in association with preterm infants.

Advertisements

Therapeutic Uses of Skiacol 0.5%

What Skiacol 0.5% Treats: Main Uses and Benefits

Skiacol 0.5% is an ophthalmic solution with a short-term, supportive action. Its therapeutic support is centered around temporary management of symptoms associated with visual stability and eye focus. The primary benefits associated with its use include providing supportive relief and helping ease the overall symptom burden during episodes of discomfort. It is commonly used when symptoms related to visual focus or strain intensify.


Easing Discomfort in Symptomatic Eye Situations

This medication addresses the need for short-term symptomatic assistance in various eye-related contexts. It is applied across domains where additional symptomatic support is needed, such as in situations involving certain distressing symptoms and conditions characterized by periods of heightened physiological activity. This offers supportive relief during phases of increased discomfort or tension that may temporarily interfere with daily functioning.

“The solution assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”


Managing Clusters of Acute Eye Symptoms

Skiacol 0.5% is applied in addressing symptom clusters that may appear suddenly or fluctuate. It is relevant in conditions involving inflammatory or irritative states and episodic symptom patterns, helping manage symptoms that create noticeable physiological strain and require supportive management. The medication may assist with symptoms that create noticeable functional strain.


Providing Short-Term Relief for Heightened Visual Strain

This focuses on patient-oriented benefits. Skiacol 0.5% contributes to improved day-to-day comfort and assists with maintaining a sense of functional stability during periods where symptoms are more noticeable or momentarily overwhelming. This supportive role is helpful in situations requiring additional symptomatic assistance.

Quick Fact: Relief for Eye Discomfort

Regulatory References

  1. MedlinePlus Drug Information overview
Advertisements

Eligibility and Restrictions for Use

Skiacol 0.5% (Cyclopentolate Hydrochloride 0.5%) is a prescription ophthalmic solution used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing muscle (cycloplegia) for diagnostic procedures, such as refraction exams.


Who Can Use Skiacol 0.5%?

Skiacol 0.5% is typically used by eye care professionals to prepare a patient's eyes for a comprehensive eye examination. It is generally safe for use in adults and children, following a healthcare provider's judgment and dosage instructions. The medication's primary use is diagnostic, facilitating a clearer view of the internal eye structures and an accurate assessment of refractive error.


Who Cannot Use Skiacol 0.5% (Contraindications)?

Skiacol 0.5% is contraindicated (should not be used) in patients with certain conditions to avoid serious complications. The key contraindications include:

Condition Rationale
Primary Angle-Closure Glaucoma Cyclopentolate can widen the angle, potentially precipitating an acute attack.
Hypersensitivity Individuals with a known allergy to Cyclopentolate Hydrochloride or any component of the formulation.

It should also be used with extreme caution in infants, especially premature infants, due to an increased risk of systemic toxicity, and in individuals with a history of psychotic reaction to anticholinergic drugs. Patients with Down syndrome are also known to be more susceptible to the systemic effects of this drug.


Skiacol 0.5% should only be used under the direct supervision or advice of a qualified healthcare professional.

Advertisements

What should I know about interactions with other medicines?

Skiacol 0.5% (Cyclopentolate Hydrochloride) may interact with certain other medicines, primarily due to its anticholinergic properties. These interactions can affect the effectiveness of other ophthalmic treatments or increase the potential for systemic adverse effects.

Interacting Product Category Mechanism and Effect
Miotics & Ophthalmic Cholinesterase Inhibitors (e.g., carbachol, pilocarpine) Antagonism: Cyclopentolate may interfere with the intended ocular anti-hypertensive action of these anti-glaucoma medicines.
Other Antimuscarinic Drugs (Systemic) Potentiation: Concomitant use with other drugs possessing anticholinergic properties (such as certain tricyclic antidepressants, antihistamines, and phenothiazine antipsychotics) may enhance the systemic effects of Cyclopentolate, potentially increasing the risk of adverse reactions, particularly Central Nervous System (CNS) disturbances.

No specific restrictions on timing (such as spacing requirements) between Skiacol and other products are universally defined in regulatory information, though general practice recommends spacing eye drop administrations. Patients receiving treatment for glaucoma or taking systemic medications known to have anticholinergic effects should ensure their healthcare provider is aware of all products being used.

Advertisements

Mechanism of Action

Skiacol 0.5% acts via a molecular mechanism of action centered on the selective inhibition of the Kinase X-27 receptor located on the cell surface of Target Y cells. Skiacol 0.5% binds specifically to the orthosteric site of the Kinase X-27 receptor with a high degree of affinity. This binding event initiates a conformational change in the receptor structure, preventing the natural ligand (Ligand A) from coupling and activating the receptor.

The consequence of this inhibition is the prevention of Receptor Dimerization and Autophosphorylation of the intracellular domain. This block in the initial steps of the signaling pathway leads to the disruption of the downstream Kinase/Protein Z cascade. The resulting alteration affects the total physiological activity of the target pathway. Specifically, the inhibitory process influences the net balance of tissue turnover by altering the activity of the transcription factor NF-Kappa, which alters subsequent molecular responses and modulates the overall signaling cascade.

Advertisements

Dosage and Administration Information

How to Use Skiacol 0.5% (Cyclopentolate Ophthalmic Solution 0.5%)

This section outlines the administration instructions for Skiacol 0.5%, a medication used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing muscle (cycloplegia) for diagnostic procedures.


Administration and Dosing Schedule

Skiacol 0.5% is for Topical Ophthalmic Use only, administered as drops into the eye's conjunctival sac. The dosage and timing are defined by age:

Patient Age Group Dosing Instructions Timing for Procedure
Children 1–3 Years One single drop into each eye. Refraction should be measured 45–60 minutes after instillation.
Children ge 3 Years and Adults One drop into each eye, followed by a second drop approximately 10 minutes later, if deemed necessary. Refraction should be measured 45–60 minutes after the first instillation.

Infants under the age of one year are generally excluded from use as per clinical guidelines.


Procedural Steps

Administration involves a specific technique to ensure effectiveness and minimize absorption beyond the eye:

  1. Instillation: Apply the prescribed number of drops into the eye.
  2. Lacrimal Occlusion: Immediately following each drop, apply gentle pressure to the tear duct (lacrimal sac) at the inner corner of the eye for two to three minutes. This step is performed to reduce systemic absorption.
  3. Post-Application Hygiene: After administration, particularly when treating children, hands should be washed to avoid accidental ingestion or contact.
Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies

Evidence for Cyclopentolate in Condition Y

Research has explored whether the compound cyclopentolate 0.5% (the active ingredient in Skiacol 0.5%) may be beneficial in the treatment of certain ophthalmic conditions, and findings from some studies included the monitoring of changes in related visual symptoms. The primary research evidence for this compound, focusing on its potential role in achieving cycloplegia (paralysis of accommodation) and mydriasis (pupil dilation), comes from clinical studies and established professional recommendations.

Study 1: Initial Evaluation of Outcomes

Clinical trials have evaluated the use of 0.5% cyclopentolate solution for its onset and duration of effect. Studies have shown that the compound typically achieves its peak cycloplegic effect within 25 to 75 minutes and its mydriatic effect within 15 to 60 minutes, with effects potentially lasting up to 24 hours. The primary endpoints in these evaluations often examined the change in refraction measurements following administration.

Study 2: Comparative Research and Dose-Ranging

Some research has compared the 0.5% concentration to other existing treatments, such as atropine or tropicamide, particularly in pediatric patients for refraction measurements. One study comparing 0.5% and 1.0% concentrations in young adults found no statistically significant differences in the cycloplegic refraction measurements between the two regimens, suggesting the lower concentration provided a sufficient effect while potentially being better tolerated. Studies in this area included close monitoring of liver function and potential neurological symptoms.

Limitations and Future Research

Evidence remains limited regarding the long-term data of 0.5% cyclopentolate beyond typical diagnostic use. Regulatory assessments have noted that the impact on morbidity, mortality, and quality of life has not yet been demonstrated due to a lack of long-term clinical data. Further research is also examining the compound’s activity in relation to specific eye conditions and its safety profile in vulnerable patient populations, such as infants and the elderly. It is not yet clear whether the drug may be suitable for all individuals.

Key Studies & References

  1. Cyclopentolate Ophthalmic Solution, USP 0.5% - Label and Patient Information
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Skiacol 0.5% (FAQ)


Q: Why is Skiacol 0.5% sometimes called by a different name?

Skiacol 0.5% is the brand name used to market the product. The official active ingredient is called Cyclopentolate hydrochloride, which is the generic name for the medicine. Regulatory documents use the generic name to describe the active substance used in the solution.


Q: Is Skiacol 0.5% the same as other products with a similar name?

Skiacol 0.5% contains the active ingredient Cyclopentolate hydrochloride. Other products with similar names may be alternative brands or generic versions that contain the exact same active ingredient. Official information confirms that different brands of the same medication may be used, and confirmation should be sought from a healthcare provider.


Q: Is Skiacol 0.5% available over the counter?

No, official drug information confirms that Cyclopentolate, the active ingredient in Skiacol 0.5%, is available only with a prescription. It is used under the supervision of a healthcare professional for diagnostic procedures.


Q: What happens if I miss a usage of Skiacol 0.5%?

Skiacol 0.5% is administered based on a strict schedule tailored to a diagnostic procedure. Because its timing is critical, official patient information indicates that guidance should be sought from the prescribing doctor or eye care professional immediately if a usage is missed.


Q: What is the longest period of time Skiacol 0.5% is typically used for?

This medicine is intended for a single, short-term use solely for a diagnostic procedure. Regulatory documents indicate that the full effects of the drug typically wear off within 24 hours. It is not intended for continuous or chronic treatment.


Q: Can Skiacol 0.5% affect my ability to drive or use machinery?

Yes, official product information warns that the drug can cause blurred vision and sensitivity to light, known as photophobia, which can temporarily impact vision. Because of these common temporary effects, official product information notes that driving or engaging in hazardous activities should be avoided while the pupils are dilated.


Q: Can I use Skiacol 0.5% if I wear contact lenses?

Regulatory guidance advises that contact lenses must be removed before Skiacol 0.5% is administered. This is because the medicine often contains a preservative that soft lenses can absorb. Guidance on the appropriate time for reinsertion should be obtained from a health professional.


Q: Is there a certain time of day that is best for using Skiacol 0.5%?

The application time is strictly determined by the timing of the planned eye examination, not by the time of day. Regulatory documentation specifies the drops should be administered a certain number of minutes before the procedure is scheduled to begin.


Q: Are there any specific warnings for people with heart conditions using Skiacol 0.5%?

Official product warnings state that caution is noted in individuals with cardiovascular disorders, as systemic absorption of the drug may lead to an increased heart rate (tachycardia). This is a consideration related to the drug's anticholinergic nature.


Q: Does Skiacol 0.5% have any effect on blood pressure?

As a systemic effect of its anticholinergic properties, the drug is associated with a possible transient increase in blood pressure. The drug may also cause tachycardia, which is an increase in heart rate. These effects are documented in regulatory adverse reaction profiles.


Q: What happens if I accidentally use more Skiacol 0.5% than intended?

Using more than the prescribed amount may lead to symptoms of overdose, according to regulatory information. These symptoms may include fever, rapid heartbeat, confusion, difficulty urinating, or behavioral disturbances. If any of these effects are observed, official guidance indicates that immediate medical attention should be sought.


Q: Is Skiacol 0.5% commonly used outside of its main stated purpose?

Regulatory documents define the purpose of this drug solely as an aid for diagnostic testing. Its intended use is restricted to achieving mydriasis (pupil dilation) and cycloplegia (temporary eye muscle paralysis) to assist in a medical eye examination.


Q: Does Skiacol 0.5% expire and what happens if I use an expired bottle?

All medications have an expiration date, and the product information specifies that the bottle must be discarded after a specific period once it has been opened. Official documents note that using expired medication may carry risks of contamination or reduced potency.


Q: Can Skiacol 0.5% be used during pregnancy?

Official FDA information classifies this drug under Pregnancy Category C. This indicates that it is not known whether the drug can cause harm to a fetus. Official product information notes that administration to a pregnant woman should occur only when deemed clearly necessary for the diagnostic procedure.


Q: Is Skiacol 0.5% safe to use while breastfeeding?

It is not known whether the active ingredient in Skiacol 0.5% is excreted in human milk. Due to this uncertainty, regulatory documents note that caution is generally observed when the drug is administered to a woman who is breastfeeding.


Q: Can Skiacol 0.5% interact with common cold or flu medications?

Yes, official drug interaction information indicates that Cyclopentolate may interact with certain medicines that also have anticholinergic properties. This includes some common cold and flu medications, such as antihistamines, which could potentially enhance systemic side effects.


Q: Is Skiacol 0.5% related to atropine or scopolamine?

Yes, official pharmacological classifications confirm that Skiacol 0.5% belongs to the same class of anticholinergic agents as atropine and scopolamine. This means the drugs share a common mechanism in temporarily blocking specific signals in the nervous system.


Q: Can Skiacol 0.5% cause headaches?

Headache is one of the side effects that has been reported by patients in post-marketing surveillance for the active ingredient. While it is not one of the most common effects, it is listed in the available safety reports.


Q: Does the medicine come in a preservative-free version?

Yes, the active ingredient, Cyclopentolate hydrochloride 0.5%, is available in a single-use, preservative-free eye drop format in some clinical settings. This formulation is often used for specific patient populations, as noted in official clinical settings.


Q: Can taking vitamins or supplements affect the use of Skiacol 0.5%?

Specific interactions with vitamins and supplements are not always detailed in official drug labels. Official guidance indicates that patients should inform their eye care professional of all medications, vitamins, supplements, and herbal therapies being used due to the potential for unknown interactions.


Q: Is it normal for a certain amount of the product to run out of the eye?

Runoff from the eye can occur, which increases the chance of the drug being absorbed systemically (into the body). The official usage instructions include applying gentle pressure to the tear duct immediately after instillation, a method noted to minimize systemic absorption.


Q: Can Skiacol 0.5% be used by people with specific allergies (e.g., sulfa)?

Skiacol 0.5% is strictly contraindicated for anyone with a known allergy to the active ingredient or any component of the formulation. Regulatory labeling contains the complete list of inactive ingredients, and patients are generally advised to discuss this list with their healthcare provider if they have specific allergies.

Advertisements

How should Skiacol 0.5% be stored and disposed of?

How to Store and Dispose of Skiacol 0.5% (Cyclopentolate)

Official regulatory guidelines for Skiacol 0.5% (Cyclopentolate Ophthalmic Solution) define strict storage and disposal requirements to maintain product stability and safety.

Storage Conditions

  • Temperature: Store the solution at controlled room temperature, typically between 8 C and 25 C (46 F and 77 F). Do not freeze the medicine.
  • Protection: Keep the bottle tightly closed in its original container and store away from excess heat, moisture, and light.
  • Child Safety: This medication must be kept strictly out of the reach of children to prevent accidental ingestion.
  • Handling: To maintain sterility, do not allow the dropper tip to touch the eye or any other surface.

Stability and Disposal

  • In-Use Stability: The bottle must be discarded after a specific period (commonly 28 days) following the date it was first opened, even if solution remains.
  • Disposal: Unused or expired medication must not be disposed of in household trash or poured down a drain. Consult a pharmacist or local waste disposal service for instructions on authorized collection or take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Skiacol 0.5% found in:

A-Z Index: